These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
171 related items for PubMed ID: 21138861
1. β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Ambrosio G, Flather MD, Böhm M, Cohen-Solal A, Murrone A, Mascagni F, Spinucci G, Conti MG, van Veldhuisen DJ, Tavazzi L, Coats AJ. Heart; 2011 Feb; 97(3):209-14. PubMed ID: 21138861 [Abstract] [Full Text] [Related]
2. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators. J Am Coll Cardiol; 2009 Jun 09; 53(23):2150-8. PubMed ID: 19497441 [Abstract] [Full Text] [Related]
3. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators. Eur Heart J; 2005 Feb 09; 26(3):215-25. PubMed ID: 15642700 [Abstract] [Full Text] [Related]
4. Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). de Boer RA, Doehner W, van der Horst IC, Anker SD, Babalis D, Roughton M, Coats AJ, Flather MD, van Veldhuisen DJ, SENIORS Investigators. Am J Cardiol; 2010 Jul 01; 106(1):78-86.e1. PubMed ID: 20609652 [Abstract] [Full Text] [Related]
5. [Role of the L-arginine/nitric oxide system in the action of nebivolol]. Brodde OE, Philipp T. Dtsch Med Wochenschr; 2006 Nov 10; 131(45):2545-50. PubMed ID: 17091442 [Abstract] [Full Text] [Related]
6. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C. J Am Coll Cardiol; 2009 Apr 28; 53(17):1532-8. PubMed ID: 19389564 [Abstract] [Full Text] [Related]
7. [Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure]. Wolf SC, Buck-Müller N, Görner S, Risler T, Brehm BR. Med Klin (Munich); 2003 Jan 15; 98(1):1-6. PubMed ID: 12540987 [Abstract] [Full Text] [Related]
8. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Dobre D, van Veldhuisen DJ, Mordenti G, Vintila M, Haaijer-Ruskamp FM, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators. Am Heart J; 2007 Jul 15; 154(1):109-15. PubMed ID: 17584562 [Abstract] [Full Text] [Related]
9. [Nebivolol: a beta blocker with vasodilator properties]. Waeber B. Praxis (Bern 1994); 2000 Apr 06; 89(15):631-3. PubMed ID: 10804847 [Abstract] [Full Text] [Related]
10. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Shibata MC, Flather MD, Böhm M, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Parkhomenko A, Soler-Soler J, Tavazzi L, Toman J, Van Veldhuisen DJ, Coats AJ, Poole-Wilson P, Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure. Int J Cardiol; 2002 Nov 06; 86(1):77-85. PubMed ID: 12243852 [No Abstract] [Full Text] [Related]
11. Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial. Cleland JG, Huan Loh P, Freemantle N, Clark AL, Coletta AP. Eur J Heart Fail; 2004 Oct 06; 6(6):787-91. PubMed ID: 15542417 [Abstract] [Full Text] [Related]
12. [Beta-1 blockade plus NO release. Additional organ protection for patients with hypertension]. MMW Fortschr Med; 2003 Oct 02; 145(40):57. PubMed ID: 14603611 [No Abstract] [Full Text] [Related]
13. Nebivolol for heart failure in the elderly. Tavazzi L. Expert Rev Cardiovasc Ther; 2007 May 02; 5(3):423-33. PubMed ID: 17489667 [Abstract] [Full Text] [Related]
15. Nitric oxide mechanisms of nebivolol. Maffei A, Lembo G. Ther Adv Cardiovasc Dis; 2009 Aug 02; 3(4):317-27. PubMed ID: 19443516 [Abstract] [Full Text] [Related]
16. Nebivolol: a third-generation beta-blocker for hypertension. Cheng JW. Clin Ther; 2009 Mar 02; 31(3):447-62. PubMed ID: 19393838 [Abstract] [Full Text] [Related]
17. Nebivolol in older adults with heart failure: reduced rates for seniors? Armstrong PW, Alexander KP. J Am Coll Cardiol; 2009 Jun 09; 53(23):2159-61. PubMed ID: 19497442 [No Abstract] [Full Text] [Related]
18. [Beta blockade plus NO release. Patients with heart failure can be loaded more]. MMW Fortschr Med; 2002 Oct 10; 144(41):57. PubMed ID: 12474368 [No Abstract] [Full Text] [Related]
19. Nebivolol: new therapy update. Sule SS, Frishman W. Cardiol Rev; 2006 Oct 10; 14(5):259-64. PubMed ID: 16924166 [Abstract] [Full Text] [Related]